Clinical trial
Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT00129948 · SGX Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00129948 |
|---|---|
| Title | Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| Official title | An Open-Label, Single-Arm, Multi-Center, Phase II Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Patients With Acute Myeloid Leukemia (AML) in Second Salvage |
| Lead sponsor | SGX Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Acute |
| Intervention type | Drug |
| Interventions | Troxatyl™ (troxacitabine) |
| Enrollment | 211 |
| Start date | Jul 1, 2005 |
| Completion | Oct 1, 2007 |
| First posted | Aug 12, 2005 |
| Last update posted | Nov 3, 2006 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: